MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear
CooperVision, Inc. · Decision date Jul 30, 2025
What did the FDA decide?
FDA records P180035/S030 as a supplement to PMA P180035, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 30, 2025.
FDA approval order statement
introduction of a new secondary packaging line at the CooperVision manufacturing facility in Mountpark, UK
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Jul 30, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P180035/S030
- Regulatory pathway
- PMA supplement
- Applicant
- CooperVision, Inc.
- Product code
- QIT
- Decision code
- OK30
- Decision date
- Jul 30, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Daily wear soft contact lens to reduce the progression of myopia.
- Applicant
- CooperVision, Inc.
- Product code
- QIT
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P180035/S030 received
Application receipt date recorded by FDA.
P180035/S030 · FDA decision
30-Day Notice
P180035/S031 · Related supplement
MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear
P180035/S032 · Related supplement
MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear
P180035/S033 · Related supplement
MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear
P180035/S034 · Related supplement
MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear
Timeline entries are records held by MedtechLedger for P180035. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P180035
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| CooperVision, Inc. | PMA supplement | Oct 28, 2025 | FDA | |
| CooperVision, Inc. | PMA supplement | Dec 17, 2025 | FDA | |
| CooperVision, Inc. | PMA supplement | Dec 23, 2025 | FDA | |
| CooperVision, Inc. | PMA supplement | Feb 17, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
CooperVision, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5870 Stoneridge Dr., Suite 1, Pleasanton, CA, 94588
Sources and methodology
- Original FDA record: P180035/S030
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


